#AstraZeneca for the first time admits its Covishield vaccine may lead to rare side effect
4651 Tuesday, 30 April, 2024, 23:24 AstraZeneca has admitted for the first time in court documents that its Covid-19 vaccine, sold globally under the brand names Covishield and Vaxzevria among others, may lead to a rare side-effect. Covishield can cause, in rare cases, a condition that leads to blood clots and low platelet count, the vaccine-maker has said in court documents. This condition is known as Thrombosis with Thrombocytopenia Syndrome (TTS). Covishield was produced by the Serum Institute of India and widely administered in the country. AstraZeneca is facing a class action lawsuit in the UK over claims that its vaccine caused deaths and severe injuries in several cases. |
#AstraZeneca for the first time admits its Covishield vaccine may lead to rare side effect
465130.04.2024, 23:24Pig kidney transplanted into living person for first time (photo)
959421.03.2024, 20:48First person dies from Alaskapox virus
1113812.02.2024, 18:06Record-breaking doctors' strike piles pressure on England's health service
1532503.01.2024, 19:30China Hospitals overwhelmed with children suffering pneumonia
1748223.11.2023, 10:18WHO Concerned by Report of Israeli Evacuation Warning to Gaza Al-Quds Hospital
1060129.10.2023, 19:00Pakistan police bust organ trafficking ring that took kidneys from hundreds
1957120.10.2023, 23:42Israel-Hamas war live: Gaza humanitarian crisis deepens amid calls for aid
1929017.10.2023, 00:30